Gainers

• Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 8.3% to $1.04 during Tuesday's after-market session. The company's market cap stands at $29.6 million.
• Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 7.55% to $2.99. The company's market cap stands at $6.7 million.
• Celularity (NASDAQ:CELU) shares moved upwards by 6.55% to $1.3. The company's market cap stands at $35.3 million.
• Citius Pharmaceuticals (NASDAQ:CTXR) shares moved upwards by 6.52% to $0.9. The market value of their outstanding shares is at $19.5 million.
• TScan Therapeutics (NASDAQ:TCRX) stock moved upwards by 6.17% to $1.35. The company's market cap stands at $85.9 million.
• SINTX Technologies (NASDAQ:SINT) shares increased by 5.74% to $2.76. The market value of their outstanding shares is at $11.4 million.

Losers

• Actuate Therapeutics (NASDAQ:ACTU) shares fell 11.7% to $2.0 during Tuesday's after-market session. The market value of their outstanding shares is at $62.1 million.
• NexGel (NASDAQ:NXGL) shares decreased by 9.83% to $0.67. The company's market cap stands at $5.4 million.
• Community Health System (NYSE:CYH) stock decreased by 8.07% to $2.85. The company's market cap stands at $436.6 million. As per the press release, Q1 earnings came out today.
• Milestone Scientific (AMEX:MLSS) shares decreased by 8.0% to $0.29. The market value of their outstanding shares is at $23.3 million.
• HeartSciences (NASDAQ:HSCS) shares declined by 6.7% to $1.95. The market value of their outstanding shares is at $6.5 million.
• Harmony Biosciences Hldgs (NASDAQ:HRMY) stock fell 5.7% to $30.31. The market value of their outstanding shares is at $1.7 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.